The ART of HIV therapies: Dopaminergic deficits and future treatments for HIV pediatric encephalopathy

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 2, 2009, Pages 193-203

  Webb, Katy M ^a,b   Mactutus, Charles F ^a   Booze, Rosemarie M ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Attention; Children; Dopamine; Encephalopathy; HIV; Language; Motor deficits; Treatment

Indexed keywords

ABC TRANSPORTER INHIBITOR; AMPHETAMINE; ANTIRETROVIRUS AGENT; EFAVIRENZ; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; GLYCOPROTEIN GP 120; LOPINAVIR PLUS RITONAVIR; MATRIX METALLOPROTEINASE INHIBITOR; METALLOTHIONEIN; METHYLPHENIDATE; MINOCYCLINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID; VIRUS RNA; ZIDOVUDINE; ZINC BINDING PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; DOPAMINE;

ANTIVIRAL ACTIVITY; ATTENTION DEFICIT DISORDER; BLOOD BRAIN BARRIER; BRAIN INFECTION; BRAIN METABOLISM; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE MARKER; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED ENCEPHALOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LANGUAGE DISABILITY; LOW DRUG DOSE; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SPEECH THERAPY; TREATMENT DURATION; VIRUS REPLICATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT CHEMOTHERAPY; BRAIN; CHILD; GROWTH, DEVELOPMENT AND AGING; PATHOLOGY; PHYSIOLOGY;

AIDS DEMENTIA COMPLEX; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; CHEMOTHERAPY, ADJUVANT; CHILD; COGNITION DISORDERS; DOPAMINE; HUMANS; MINOCYCLINE;

EID: 64049101407     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.7.2.193     Document Type: Review

References (84)

1. An SF, Groves M, Gray F, Scaravilli F. Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. J. Neuropathol. Exp. Neurol. 58(11), 1156-1162 (1999).
2. Koenig S, Gendelman HE, Orenstein JM et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233(4768), 1089-1093 (1986).
3. Gelbard HA, Epstein LG. HIV-1 encephalopathy in children. Curr. Opin. Pediatr. 7(6), 655-662 (1995).
4. Gartner S. HIV infection and dementia. Science 287(5453), 602-604 (2000).
5. Persidsky Y, Zheng J, Miller D, Gendelman HE. Mononuclear phagocytes mediate blood - brain barrier compromise and neuronal injury during HIV-1-associated dementia. J. Leukoc. Biol. 68(3), 413-422 (2001).
6. Budka H, Costanzi G, Cristina S et al. Brain pathology induced by infection with the human immunodeficiency virus (HIV). A histological, immunocytochemical, and electron microscopical study of 100 autopsy cases. Acta Neuropathol. 75(2), 185-198 (1987).
7. Epstein LG, Gendelman HE. Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol. 33(5), 429-436 (1993).
8. Kaul M, Lipton SA. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr. HIV Res. 4(3), 307-318 (2006).
9. Belman AL. HIV-1 infection and AIDS. Neurol. Clin. 20(4), 983-1011 (2002).
10. Wolters PL, Brouwers P, Moss HA, Pizzo PA. Differential receptive and expressive language functioning of children with symptomatic HIV disease and relation to CT scan brain abnormalities. Pediatrics 95(1), 112-119 (1995).
11. Blanchette N, Smith ML, Fernandes-Penney A, King S, Read S. Cognitive and motor development in children with vertically transmitted HIV infection. Brain Cogn. 46(1-2), 50-53 (2001).
12. Epstein LG, Sharer LR, Oleske JM et al. Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics 78(4), 678-687 (1986).
13. Epstein LG, Sharer LR, Goudsmit J. Neurological and neuropathological features of human immunodeficiency virus infection in children. Ann. Neurol. 23(Suppl.), S19-S23 (1988).
14. Lobato MN, Caldwell MB, Ng P, Oxtoby MJ. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Pediatric Spectrum of Disease Clinical Consortium. J. Pediatr. 126(5 Pt 1), 710-715 (1995).
15. Mintz M. Clinical features. In: The Neurology of AIDS (2nd Edition). Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S (Eds). Oxford University Press, NY, USA 639-658 (2005).
16. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 239(4840), 586-592 (1988).
17. Mintz M. Neurological and developmental problems in pediatric HIV-infection. J. Nutr. 126(10 Suppl.), S2663-S2673 (1996).
18. Shanbhag MC, Rutstein RM, Zaoutis T, Zhao H, Chao D, Radcliffe J. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy. Arch. Pediatr. Adolesc. Med. 159(7), 651-656 (2005).
19. Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220(4599), 868-871 (1983).
20. Rogers MF, Thomas PA, Starcher ET, Noa MC, Bush TJ, Jaffe HW. Acquired immunodeficiency syndrome in children: report of the Centers for Disease Control National Surveillance, 1982 to 1985. Pediatrics 79(6), 1008-1014 (1987).
21. Newell ML, Brahmbhatt H, Ghys PD. Child mortality and HIV infection in Africa: a review. AIDS 18(Suppl. 2), S27-S34 (2004).
22. Van Rie A, Mupuala A, Dow A. Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged children in Kinshasa, Democratic Republic of the Congo. Pediatrics 122(1), e123-e128 (2008).
23. Van Rie A, Harrington PR, Dow A, Robertson K. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective. Eur. J. Paediatr. Neurol. 11(1), 1-9 (2007).
24. Chiriboga CA, Fleishman S, Champion S, Gaye-Robinson L, Abrams EJ. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J. Pediatr. 146(3), 402-407 (2005).
25. Willen EJ. Neurocognitive outcomes in pediatric HIV. Ment. Retard. Dev. Disabil. Res. Rev. 12(3), 223-228 (2006).
26. Koekkoek S, Eggermont L, De Sonneville L et al. Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease. J Neurol. 253(12), 1615-1624 (2006).
27. McCoig C, Castrejón MM, Castaño E et al. Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J. Pediatr. 141(1), 36-44 (2002).
28. Wood LV. Antiretroviral therapy in children. In: The Neurology of AIDS (2nd Edition). Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S (Eds). Oxford University Press, NY, USA 693-710 (2005).
29. Blanchette N, Smith ML, King S, Fernandes-Penney A, Read S. Cognitive development in school-age children with vertically transmitted HIV infection. Dev. Neuropsychol. 21(3), 223-241 (2002).
30. Hazra R, Jankelevich S, Mackall CL et al. Immunologic, virologic, and neuropsychologic responses in human immunodeficiency virus-infected children receiving their first highly active antiretroviral therapy regimen. Viral Immunol. 20(1), 131-141 (2007).
31. Martin SC, Wolters PL, Toledo-Tamula MA, Zeichner SL, Hazra R, Civitello L. Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). Dev. Neuropsychol. 30(2), 633-657 (2006).
32. Havens JF, Whitaker AH, Feldman JF, Ehrhardt AA. Psychiatric morbidity in school-age children with congenital human immunodeficiency virus infection: a pilot study. J. Dev. Behav. Pediatr. 15(3 Suppl.), S18-S25 (1994).
33. Moss HA, Wolters PL, Brouwers P, Hendricks ML, Pizzo PA. Impairment of expressive behavior in pediatric HIV-infected patients with evidence of CNS disease. J. Pediatr. Psychol. 21(3), 379-400 (1996).
34. Wolters PL, Brouwers P. Evaluation of neurodevelopmental deficits in children with HIV-1 infection. In: The Neurology of AIDS (2nd Edition). Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S (Eds). Oxford University Press, NY, USA 667-682 (2005).
35. Misdrahi D, Vila G, Funk-Brentano I, Tardieu M, Blanche S, Mouren-Simeoni MC. DSM-IV mental disorders and neurological complications in children and adolescents with human immunodeficiency virus type 1 infection (HIV-1). Eur. Psychiatry 19(3), 182-184 (2004).
36. Mialky E, Vagnoni J, Rutstein R. School-age children with perinatally acquired HIV infection: medical and psychosocial issues in a Philadelphia cohort. AIDS Patient Care STDS 15(11), 575-579 (2001).
37. Engle RW, Tuholski SW, Laughlin JE, Conway AR. Working memory, short-term memory, and general fluid intelligence: a latent-variable approach. J Exp. Psychol. Gen. 128(3), 309-331 (1999).
38. Mellins CA, Smith R, O'Driscoll P et al. High rates of behavioral problems in perinatally HIV-infected children are not linked to HIV disease. Pediatrics 111(2), 384-393 (2003).
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (4th Edition). American Psychiatric Publishing Inc., DC, USA (2000).
40. Wolters PL, Brouwers P, Civitello L, Moss HA. Receptive and expressive language function of children with symptomatic HIV infection and relationship with disease parameters: a longitudinal 24-month follow-up study. AIDS 11(9), 1135-1144 (1997).
41. Mintz M, Tardieu M, Hoyt L, McSherry G, Mendelson J, Oleske J. Levodopa therapy improves motor function in HIV-infected children with extrapyramidal syndromes. Neurology 47(6), 1583-1585 (1996).
42. Kieburtz KD, Epstein LG, Gelbard HA, Greenamyre JT. Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Arch. Neurol. 48(12), 1281-1284 (1991).
43. Lopez OL, Smith G, Meltzer CC, Becker JT. Dopamine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry Neuropsychol. Behav. Neurol. 12(3), 184-192 (1999).
44. Silvers JM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM. Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor. Neurotoxicology 28(6), 1184-1190 (2007).
45. Aksenova MV, Silvers JM, Aksenov MY et al. HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci. Lett. 395(3), 235-239 (2006).
46. Silvers JM, Aksenov MY, Aksenova MV et al. Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains. J. Neurovirol. 12(2), 140-145 (2006).
47. Zgaljardic DJ, Borod JC, Foldi NS et al. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease. J. Clin. Exp. Neuropsychol. 28(7), 1127-1144 (2006).
48. Fitting S, Booze RM, Mactutus CF. Neonatal intrahippocampal injection of the HIV-1 proteins gp120 and Tat: differential effects on behavior and the relationship to stereological hippocampal measures. Brain Res. 1232, 139-154 (2008).
49. Wiley CA, Soontornniyomkij V, Radhakrishnan L et al. Distribution of brain HIV load in AIDS. Brain Pathol. 8(2), 277-284 (1998).
50. Loveland KA, Stehbens JA, Mahoney EM et al. Declining immune function in children and adolescents with hemophilia and HIV infection: effects on neuropsychological performance. Hemophilia Growth and Development Study. J. Pediatr. Psychol. 25(5), 309-322 (2000).
51. Eilers M, Roy U, Mondal D. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp. Biol. Med. (Maywood) 233(9), 1149-1160 (2008).
52. Banks WA. The blood - brain barrier: its structure and function. In: The Neurology of AIDS (2nd Edition). Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S (Eds). Oxford University Press, NY, USA 108-110 (2005).
53. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. Quantitative assessment: of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood - brain barrier. Pharm. Res. 22(8), 1259-1268 (2005).
54. Ronaldson PT, Lee G, Dallas S, Bendayan R. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm. Res. 21(5), 811-818 (2004).
55. Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA. Glycogen synthase kinase 3 β (GSK-3β) as a therapeutic target in neuroAIDS. J. Neuroimmune Pharmacol. 2(1), 93-96 (2007).
56. Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc. Natl Acad. Sci. USA 97(14), 8075-8080 (2000).
57. Sui Z, Sniderhan LF, Fan S et al. Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3β to antagonize nuclear factor-κB survival pathway in neurons. Eur. J. Neurosci. 23(10), 2623-2634 (2006).
58. Gelbard HA, Nottet HS, Swindells S et al. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J. Virol. 68(7), 4628-4635 (1994).
59. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase-3β contributes to Tat-mediated neurotoxicity. J. Neurochem. 73(2), 578-586 (1999).
60. Dou H, Birusingh K, Faraci J et al. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J. Neurosci. 23(27), 9162-9170 (2003).
61. DiCenzo R, Peterson D, Cruttenden K et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrbb. Agents Chemother. 48(11), 4328-4331 (2004).
62. Schifitto G, Peterson DR, Zhong J et al. Valproic acid-adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 66(6), 919-921 (2006).
63. Gendelman HE. Biomarkers, laboratory, and animal models for the design and development of adjunctive therapies for HIV-1 dementia and other J. Neuroimmune Pharmacol. 2(1), 8-13 (2007).
64. Zink MC, Uhrlaub J, DeWitt J et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293(16), 2003-2011 (2005).
65. Zink MC, Suryanarayana K, Mankowski JL et al. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J. Virol. 73(12), 10480-10488 (1999).
66. Murray EA, Rausch DM, Lendvay J, Sharer LR, Eiden LE. Cognitive and motor impairments associated with SIV infection in rhesus monkeys. Science 255, 1246-1249 (1992).
67. Mitchell CD. HIV-1 encephalopathy among perinatally infected children: neuropathogenesis and response to highly active antiretroviral therapy. Ment. Retard. Dev. Disabil. Res. Rev. 12(3), 216-222 (2006).
68. Meinild AK, Sitte HH, Gether U. Zinc potentiates an uncoupled anion conductance associated with the dopamine transporter. J. Biol. Chem. 279(48), 49671-49679 (2004).
69. Hwang CK, D'Souza UM, Eisch AJ et al. Dopamine receptor regulating factor, DRRF: a zinc finger transcription factor. Proc. Natl Acad. Sci. USA 98(13), 7558-7563 (2001).
70. Hong SJ, Huh Y, Chae H, Hong S, Lardaro T, Kim KS. GATA-3 regulates the transcriptional activity of tyrosine hydroxylase by interacting with CREB. J. Neurochem. 98(3), 773-781 (2006).
71. Suryadevara R, Holter S, Borgmann K et al. Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 44(1), 47-56 (2003).
72. Latronico T, Liuzzi GM, Riccio P et al. Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. AIDS 21(6), 677-684 (2007).
73. Kim EH, Kim TS, Sun W et al. Differential regulation of metallothionein-I and metallothionein-IL mRNA expression in the rat brain following traumatic brain injury. Mol. Cells 13(3), 326-331 (2004).
74. Chung RS, Penkowa M, Dittmann J et al. Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. J. Biol. Chem. 283(22), 15349-15358 (2008).
75. Aksenov MY, Hasselrot U, Wu G et al. Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res. 987(1), 1-9 (2003).
76. Hidalgo J, Aschner M, Zatta P, Vasák M. Roles of the metallothionein family of proteins in the central nervous system. Brain Res. Bull. 55(2), 133-145 (2001).
77. Schwartz L, Civitello L, Dunn-Pirio A et al. Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue. J. Neurovirol. 13(3), 274-283 (2007).
78. Okamoto S, Kang YJ, Brechtel CW et al. HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest. Cell Stem Cell 1(2), 230-236 (2007).
79. Krathwohl MD, Kaiser JL. HIV-1 promotes quiescence in human neural progenitor cells. J. Infect. Dis. 190(2), 216-226 (2004).
80. Roy NS, Wang S, Jiang L et al. In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus. Nat. Med. 6(3), 271-277 (2000).
81. Schwartz L, Major EO. Neural progenitors and HIV-1-associated central nervous system disease in adults and children. Curr. HIV Res. 4(3), 319-327 (2006).
82. Sanes DH, Reh JA, Harris WA. Birth and migration. In: development of the Nervous System. Sanes DH, Reh TA, Harris WA (Eds). Academic Press, CA, USA 90 (2000).
83. Reid W, Sadowska M, Denaro F et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc. Natl Acad. Sci. USA 98(16), 9271-9276 (2001).
84. Webb KM, Fitting S, Mactutus CF, Booze RM. Behavioral characterization of HIV-1 transgenic rats. Presented at: 13th Society on NeuroImmune Pharmacology Conforence. Salt Lake City, UT, USA, 11-14 April 2007.